Nanobiotix appoints CordenPharma as CMO for potential nanoparticle-based cancer treatment

By Zachary Brennan

- Last updated on GMT

Nanobiotix appoints CordenPharma as CMO for potential nanoparticle-based cancer treatment

Related tags Cancer

The late clinical-stage nanomedicine company Nanobiotix has selected CordenPharma as its contract manufacturing partner. 

The deal comes as CordenPharma plans to open a new manufacturing line at its France site, which is one of eight cGMP facilities across Europe and the US, and the new line will increase production capacity 25-fold. 

The new line is expected manufacture NBTXR3, Nanobiotix’s lead product, which is comprised of Hafnium Oxide nanoparticles that can be injected directly into tumors. With the application of radiotherapy, these nanoparticles absorb X-rays and have the potential to significantly enhance the radiation dose within the cancer cells without increasing the dose to the surrounding healthy tissues, the company says. 

Nanobiotix expects its product to win CE marking in 2016, and is therefore preparing to scale-up production to meet the needs of the expected commercialization. The company also anticipates future demand from clinical trials in the coming years in Europe and the US.  

Yves Michon, president of CordenPharma said: “Nanobiotix’s product, NBTXR3 is a fascinating product – not only with respect to its properties, but also in its manufacture. We are working closely with Nanobiotix to ensure a seamless process and manage the scale-up of the product.​”

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Related suppliers

Follow us

Products

View more

Webinars